Q1 2019 13F Holders as of 3/31/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108M
-
Number of holders
-
87
-
Total 13F shares, excl. options
-
37.4M
-
Shares change
-
-1.19M
-
Total reported value, excl. options
-
$224M
-
Value change
-
-$10.8M
-
Put/Call ratio
-
4.07
-
Number of buys
-
47
-
Number of sells
-
-39
-
Price
-
$5.99
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q1 2019
108 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock as of Q1 2019.
Aclaris Therapeutics, Inc. - Common Stock (ACRS) has 87 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.4M shares
of 108M outstanding shares and own 34.51% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (5.89M shares), FRANKLIN RESOURCES INC (4M shares), BlackRock Inc. (3.13M shares), Broadfin Capital, LLC (2.03M shares), Sofinnova Investments, Inc. (1.91M shares), D. E. Shaw & Co., Inc. (1.85M shares), VANGUARD GROUP INC (1.84M shares), Rock Springs Capital Management LP (1.7M shares), Vivo Capital, LLC (1.65M shares), and MFN Partners Management, LP (1.5M shares).
This table shows the top 87 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.